Veteran-Owned • U.S. pharmacy-compounded

A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.

PT-141 (Bremelanotide) Clinical Protocol

Veteran Owned • U.S. pharmacy-compoundedDirect-to-Door Delivery

Advanced Peptide

PT-141 (Bremelanotide)

Centrally Acting Melanocortin Receptor Agonist

Hormonal & SexualHormonal, reproductive and sexual health

Direct Door Delivery

Compounded Preparation> 99% Purity • 5mL Liquid (Liquid)

Compound Specifications

FormatLiquid

StorageRefrigerate at 2°C - 8°C.

Fulfillment 100% Shipped Direct

OriginU.S. pharmacy-compounded

Advanced Peptide•USA Veteran Owned

PT-141 (Bremelanotide)

Centrally Acting Melanocortin Receptor Agonist

A synthetic peptide analog of alpha-MSH evaluated in clinical studies for its interactions with central melanocortin MC3 and MC4 receptors, explored under medical guidance for individuals experiencing sexual arousal and desire concerns.

Clinical Mechanism of Action

Acts as an agonist at central melanocortin receptors within the hypothalamus, modulating neural pathways involved in sexual response and arousal signaling.

Documented Therapeutic Benefits

Centrally mediated mechanism evaluated for sexual desire and arousal pathways

Investigated in both male and female clinical research contexts

Operates via neurological melanocortin pathways rather than direct peripheral vascular vasodilation

Available under personalized clinical evaluation by a licensed healthcare provider

Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.

Clinical Administration Protocol

Subcutaneous injection 1 to 2 hours prior to desired effect.

Order on Online Store

Door Delivery Only: We do not offer in-clinic pickup. All medications are dispatched directly to your residential address in cold-chain packaging.

Frequently Asked Clinical Questions

How does PT-141 differ from PDE-5 inhibitors?

PT-141 engages central melanocortin receptors in the brain to modulate sexual response pathways, unlike PDE-5 inhibitors which act on peripheral blood vessels.